硕迪生物 GPCR 深 沪
等待开盘 05-18 09:30:00 美东时间
38.69
-1.150
-2.89%
华盛通- 最 高39.80
- 今 开39.01
- 成交量 46.73万股
- 最 低 38.27
- 昨 收 39.84
- 总市值 27.50亿
- 52周最高 94.90
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 15.80
- 委 比 -83.55%
- 总股本 7107.12万
- 历史最高 94.90
- 量 比 0.70
- 振 幅 3.84%
- 历史最低 13.22
- 每 手 1
- 风险率 21.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报速睇 | 硕迪生物 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损0.76亿美元，同比亏损扩大62.2%
华盛资讯5月8日讯，硕迪生物公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损0.76亿美元，同比亏损扩大62.2%。
05-08 08:38
Structure Therapeutics Q1 EPS $(0.35), Inline
Structure Therapeutics (NASDAQ:GPCR) reported quarterly losses of $(0.35) per share which met the analyst consensus estimate. This is a 29.63 percent decrease over losses of $(0.27) per share from the same period last
05-08 04:58
美股大行评级 | 美银大幅上调西部数据、希捷科技目标价！宝洁、Baker Hughes、Flagstar Bank、斯伦贝谢等获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从48美元升至49美元；Chardan Capital：维持Intellia Therapeutics"买入"评级，目标价从27美元升至30美元
04-28 10:07
Canaccord Genuity Initiates Coverage On Structure Therapeutics with Buy Rating, Announces Price Target of $101
Canaccord Genuity analyst Edward Nash initiates coverage on Structure Therapeutics (NASDAQ:GPCR) with a Buy rating and announces Price Target of $101.
04-27 20:58
Structure Therapeutics Appoints Matthew Lang COO
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the
04-15 04:09
What's Going On With Structure Therapeutics Stock On Wednesday?
Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.
04-02 02:07
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Structure Therapeutics shares are trading higher after the company announced topline data from the Phase 2 ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity.
Structure Therapeutics shares are trading higher after the company announced to...
03-16 20:50
